Abstract
The assessment of systemic inflammation by means of laboratory tests often complements the results of medical examination. Traditionally, the erythrocyte sedimentation rate and leukocytosis with left shift are diagnostic markers for inflammatory and infectious diseases. The levels of acute-phase proteins—especially C-reactive protein—are used to assess both the presence of inflammation and any response to treatment. The determination of C-reactive protein levels may be advised in three types of pathological situation: infection, acute or chronic inflammation, and evaluation of metabolic risk. Procalcitonin is useful as a marker of sepsis and severe infection. The concentration of serum amyloid A predicts the chances of survival of patients with secondary (AA) amyloidosis. Ferritin and its glycosylated form are of interest in the study of specific diseases such as adult-onset Still's disease. Markers of cartilage and bone turnover are complementary to these markers of inflammation. Although cytokine serum levels are transiently crucial to the generation of inflammation, their usefulness in the clinic is still under investigation. Serum concentrations of cytokine inhibitors or soluble cytokine receptors, as well as the clinical response of patients to treatment with cytokine antagonists, might generate important information for monitoring autoinflammatory diseases.
Key Points
-
Traditionally, leukocytosis with left shift and erythrocyte sedimentation rate are of diagnostic value in predicting infectious and inflammatory diseases
-
The progress of inflammation can be monitored in most conditions by determining the serum levels of C-reactive protein
-
Procalcitonin serum levels have definite advantages for the evaluation of sepsis and severe infections
-
Levels of serum amyloid A are associated with the outcome of secondary (AA) amyloidosis
-
Levels of ferritin and its glycosylated form are useful parameters in adult-onset Still's disease
-
Serum levels of soluble cytokine receptors or cytokine inhibitors, as well as the response to anticytokine treatment, may improve insight into autoinflammatory diseases
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Seebach JD et al. (1997) The diagnostic value of the neutrophil left shift in predicting inflammatory and infectious disease. Am J Clin Pathol 107: 582–591
Xing Z et al. (1998) IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101: 311–320
Jones SA et al. (2001) The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 15: 43–58
Marnell L et al. (2005) C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 117: 104–111
Griselli M et al. (1999) C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 190: 1733–1740
Gershov D et al. (2000) C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192: 1353–1364
Russell AI et al. (2004) Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 13: 137–147
Shin KC et al. (2001) Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis 60: 988–989
Pearson TA et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499–511
Ridker PM et al. (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557–1565
Cook NK et al. (2006) The effect of including C-reactive protein in cardiovascular risk prediction model for women. Ann Intern Med 145: 21–29
Folsom AR et al. (2006) An assessment of the incremental coronary risk prediction using C-reactive protein and other novel risk markers. The atherosclerosis risk in community study. Ann Intern Med 166: 1368–93
Weyand CM et al. (1999) Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 159: 577–584
Pepys MB and Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111: 1805–1812
Müller B et al. (2001) Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 86: 396–404
Müller B et al. (2004) Limits to the use of the procalcitonin level as a diagnostic marker. Clin Infect Dis 39: 1867–1868
Assicot M et al. (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341: 515–518
Simon L et al. (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39: 206–217
Nishikura T (1999) Procalcitonin (PCT) production in a thyroidectomized patient. Intensive Care Med 25: 1031
Nylen E et al. (2003) The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis 36: 823–824
Delèvaux I et al. (2003) Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 62: 337–340
Arkader R et al. (2006) Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child 91: 117–120
Richard-Lenoble D et al. (1997) Changes in procalcitonin and interleukin 6 levels among treated African patients with different clinical forms of malaria. Trans R Soc Trop Med Hyg 91: 305–306
Schwenger V et al. (1998) CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 26: 274–276
Scire CA et al. (2006) Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 24: 123–128
Malle E and De Beer FC (1996) Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 26: 427–435
Tam SP et al. (2002) Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A. J Lipid Res 43: 1410–1420
Thorn CF et al. (2004) Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol 59: 152–158
Mullan RH et al. (2006) Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum 54: 105–114
Yamada T et al. (2001) Relative serum amyloid A (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 60: 124–127
Gillmore JD et al. (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358: 24–29
Efthimiou P et al. (2006) Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 65: 564–572
Fautrel B et al. (2001) Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol 28: 322–329
Kawaguchi Y et al. (2001) Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum 44: 1716–1717
Navarro MA et al. (2005) Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation. Cytokine 31: 52–63
Nofer JR et al. (2006) Low density lipoproteins inhibit the Na+/H+ antiport in human platelets via activation of p38MAP kinase. Biochem Biophys Res Commun 340: 751–757
Hyka N et al. (2001) Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97: 2381–2389
Chait A et al. (2005) Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 46: 389–403
Ansell BJ et al. (2005) High-density lipoprotein function recent advances. J Am Coll Cardiol 46: 1792–1798
Chenaud C et al. (2004) Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med 32: 632–637
Marchesi S et al. (2005) Acute inflammatory state during influenza infection and endothelial function. Atherosclerosis 178: 345–350
Lahita RG et al. (1993) Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36: 1566–1574
Park YB et al. (1999) Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26: 1701–1704
Möller B and Villiger P (2006) Inhibition of IL-1, IL-6, and TNF-alpha in immune mediated inflammatory diseases. Spinger Semin Immun 27: 391–408
Roux-Lombard P et al. (1993) Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 36: 485–489
Gabay C et al. (1997) Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24: 303–308
Hull KM et al. (2002) The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 81: 349–368
Drewe E et al. (2004) Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 43: 1405–1408
Stojanov S and Kastner DL (2005) Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 17: 586–599
Seckinger P et al. (1987) A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol 139: 1546–1549
Dinarello CA (2005) Blocking IL-1 in systemic inflammation. J Exp Med 201: 1355–1359
Sturfelt G et al. (1997) Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 36: 1283–1289
Miki C et al. (2005) Deficiency in systemic interleukin-1 receptor antagonist production as an operative risk factor in malnourished elderly patients with colorectal carcinoma. Crit Care Med 33: 177–180
Weiss G and Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352: 1011–1023
Punzi L et al. (2005) New biochemical insights into the pathogenesis of osteoarthritis and the role of laboratory investigations in clinical assessment. Crit Rev Clin Lab Sci 42: 279–309
Garnero P (2006) Biochemical markers in osteoarthritis: will they measure up? Nat Clin Pract Rheumatol 2: 116–117
Saxne T et al. (2006). Biomarkers for cartilage and bone in rheumatoid arthritis. In Rheumatoid Arthritis: New Frontiers in Pathogenesis and Treatment, edn 2 301–313 (eds Firestein GS et al.) Oxford: Oxford University Press
Roux-Lombard P et al. (2001) Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology 40: 544–551
Van der Pouw Kraan TC et al. (2007) Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis [doi: 10.1136/ard.2006.063412]
Duff GW (2000) Genetic variations in cytokines and relevance to inflammation and diseases. In The Cytokine network frontiers in molecular biology, (vol 25) 152 (ed Balkwill F) Oxford: Oxford University Press
Chen H et al. (2006) Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Human Mol Gen 15: 519–529
Hueber W and Robinson WH (2006) Proteomic biomarkers for autoimmune disease. Proteomics 6: 4100–4105
Acknowledgements
We thank F Wollheim and T Saxne for their helpful advice about markers of cartilage and bone turnover.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Dayer, E., Dayer, JM. & Roux-Lombard, P. Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat Rev Rheumatol 3, 512–520 (2007). https://doi.org/10.1038/ncprheum0572
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0572
This article is cited by
-
Amelioration of complete Freund’s adjuvant-induced arthritis by Calotropis procera latex in rats
Future Journal of Pharmaceutical Sciences (2021)
-
Poor prognostic impact of high serum ferritin levels in patients with a lower risk of diffuse large B cell lymphoma
International Journal of Hematology (2020)
-
Anti-arthritic activity of cell wall content of Lactobacillus plantarum in freund’s adjuvant-induced arthritic rats: involvement of cellular inflammatory mediators and other biomarkers
Inflammopharmacology (2018)
-
Optimal combinations of acute phase proteins for detecting infectious disease in pigs
Veterinary Research (2011)